These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 11249689)

  • 41. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.
    Stanley M; Gissmann L; Nardelli-Haefliger D
    Vaccine; 2008 Aug; 26 Suppl 10():K62-7. PubMed ID: 18847558
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
    Daemen T; Regts J; Holtrop M; Wilschut J
    Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
    Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
    Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
    Villa LL
    Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of the immune system in anogenital human papillomavirus.
    Frazer IH
    Australas J Dermatol; 1998 Nov; 39 Suppl 1():S5-7. PubMed ID: 9842093
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma.
    Devaraj K; Gillison ML; Wu TC
    Crit Rev Oral Biol Med; 2003; 14(5):345-62. PubMed ID: 14530303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis, properties and applications of papillomavirus-like particles.
    Sapp M; Volpers C; Streeck RE
    Intervirology; 1996; 39(1-2):49-53. PubMed ID: 8957669
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Progress in prophylactic and therapeutic vaccines for human papillomavirus infection.
    Stanley MA
    Expert Rev Vaccines; 2003 Jun; 2(3):381-9. PubMed ID: 12903803
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human papillomavirus vaccines for cervical cancer.
    Murakami M; Gurski KJ; Steller MA
    J Immunother; 1999 May; 22(3):212-8. PubMed ID: 10335480
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers.
    Ling M; Kanayama M; Roden R; Wu TC
    J Biomed Sci; 2000; 7(5):341-56. PubMed ID: 10971133
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Presence of antibodies to human papillomavirus virus-like particles (VLPs) in 11-13-year-old schoolgirls.
    Cubie HA; Plumstead M; Zhang W; de Jesus O; Duncan LA; Stanley MA
    J Med Virol; 1998 Nov; 56(3):210-6. PubMed ID: 9783687
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.
    Kowalczyk DW; Wlazlo AP; Shane S; Ertl HC
    Vaccine; 2001 May; 19(25-26):3583-90. PubMed ID: 11348726
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine.
    Jochmus I; Schäfer K; Faath S; Müller M; Gissmann L
    Arch Med Res; 1999; 30(4):269-74. PubMed ID: 10573627
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human papillomavirus vaccines--immune responses.
    Stanley M; Pinto LA; Trimble C
    Vaccine; 2012 Nov; 30 Suppl 5():F83-7. PubMed ID: 23199968
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune responses to human papilloma viruses.
    Stanley MA
    Indian J Med Res; 2009 Sep; 130(3):266-76. PubMed ID: 19901436
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy.
    Liu WJ; Zhao KN; Gao FG; Leggatt GR; Fernando GJ; Frazer IH
    Vaccine; 2001 Dec; 20(5-6):862-9. PubMed ID: 11738751
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Role of macrophages in papillomavirus infections].
    Bianchi A; Dachez R; Pollini G; Monsonego J; Alonso JM
    Pathol Biol (Paris); 1997 Feb; 45(2):165-8. PubMed ID: 9247039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunologic responses to human papillomavirus infection.
    Gissmann L
    Obstet Gynecol Clin North Am; 1996 Sep; 23(3):625-39. PubMed ID: 8869949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.